The potential cardioprotective effects of SGLT-2is or SGLT-2/1is are of great promise and deserve deeper researches, the ongoing trials of the class of agent focus on heart failure patients with/without T2D will show us more hope for heart failure treatment. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.